Trump Administration Takes Steps to Reclassify Medical Cannabis, But Legalization Still Pending

In a significant policy shift, the Trump administration has announced the reclassification of state-licensed medical cannabis, now regarded as a less dangerous drug under federal regulations. This change, signed by Acting Attorney General Todd Blanche on April 23, does not legalize cannabis for recreational or medical use but alters its regulatory status, reflecting a growing recognition of its potential medical benefits.

The reclassification moves cannabis from a Schedule I drug, a category reserved for substances deemed to have a high potential for abuse and no accepted medical use—like heroin—to Schedule III. This change aligns cannabis more closely with medications that have recognized medical applications, such as Tylenol with codeine.

While the reclassification does not alter the legal status of cannabis at the federal level, it opens up new opportunities for businesses and researchers. State-licensed medical cannabis companies will benefit from tax deductions previously unavailable to them, potentially easing some of the financial burdens they face due to conflicting state and federal laws. Additionally, researchers will encounter fewer barriers when studying cannabis, allowing for a more thorough investigation into its therapeutic effects.

President Trump indicated that the decision was influenced by numerous appeals from advocates seeking to ease restrictions on cannabis. In a statement from the Department of Justice, Blanche emphasized that this action would enhance access to medical treatment options and facilitate research on the safety and efficacy of cannabis, ultimately benefiting patients and healthcare providers.

Despite this policy shift, cannabis remains illegal at the federal level. A hearing scheduled for June aims to explore broader changes to cannabis classification, but until then, the substance’s federal status remains unchanged. Currently, 48 states permit some form of medical or recreational cannabis use, with only Idaho and Kansas lacking any legal cannabis programs.

The reclassification is expected to have a profound impact on the cannabis industry. Terry Mendez, CEO of Safe Harbor Financial, described the order as “the most significant federal action on cannabis policy in more than 50 years.” The change will not only affect operators but also investors, lenders, and real estate partners involved in the cannabis sector.

Researchers are optimistic about the implications of the new classification. With reduced regulatory hurdles, scientists will have greater access to cannabis for research purposes, facilitating studies that could validate the medical benefits reported by many patients. Sasha Kalcheff-Korn, executive director of Realm of Caring, remarked that the rescheduling will simplify research efforts, promoting a better scientific understanding of cannabinoid therapies.

Nevertheless, caution accompanies this policy shift. Some experts warn that increased access must be balanced with public health considerations, particularly concerning youth mental health issues linked to cannabis use. Pam Jenkins, CEO of Shatterproof, stressed the importance of responsible policymaking that protects young people and provides clear guidance to clinicians.

As the June hearing approaches, the cannabis community and advocates will be closely watching to see if further changes to federal cannabis policy will follow this reclassification.